Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis

Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis-a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial

-Evaluate the efficacy and safety of Shenyankangfu Tablets to control the proteinuria of patients with primary glomerulonephritis compare with Losartan potassium.

Inclusion

• Diagnosed with primary glomerulonephritis
• Aged from 18 to 70 years，male or female
• Blood pressure can be controlled ≤140/90mmHg
• GFR≥45ml/min/1.73㎡
• 0.5g≤24 hours proteinuria≤3.0g
• Traditional Chinese medicine syndrome conform Qi-Yin Deficiency
• Obtain the agreement of patients or their guardians, and signed informed consent file

Exclusion Criteria:

• secondary nephropathy
• Take the glucocorticoid,immunosuppressants and Tripterygium drug in the last 12 months
• Take other Chinese patent medicine and decoction which can reduce proteinuria in the last 2 weeks
• Take renin-angiotensin system blockers in last 4 weeks
• Combined with severe primary disease of heart, brain, liver and hematopoietic system, or other serious diseases can affect patient's life
• Pregnant or lactating women
• Allergic predisposition or known to be allergic to the drug composition
• Blood presser <90/60mmHg
• With unilateral or bilateral renal artery stenosis
• With mental disorders and poor compliance
• Be suspected or confirmed with alcohol, drug abuse history
• Be participating in another clinical study at the same period